In yesterday’s Wall Street session, Abeona Therapeutics Inc. (NASDAQ:ABEO) shares traded at $3.27, up 16.79% from the previous session.
As of this writing, 2 analysts cover Abeona Therapeutics Inc. (NASDAQ:ABEO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $20.00, we find $29.00. Given the previous closing price of $2.80, this indicates a potential upside of 935.71 percent. ABEO stock price is now 25.61% away from the 50-day moving average and -11.01% away from the 200-day moving average. The market capitalization of the company currently stands at $53.76M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $29.00 as their price target over the next twelve months.
With the price target maintained at $4, Cantor Fitzgerald recently Upgraded its rating from Neutral to Overweight for Abeona Therapeutics Inc. (NASDAQ: ABEO). On September 18, 2020, B. Riley FBR recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘SVB Leerink’ rates the stock as ‘Outperform’.
In other news, Amoroso Michael, Director sold 1,002 shares of the company’s stock on Mar 03. The stock was sold for $2,385 at an average price of $2.38. Upon completion of the transaction, the Director now directly owns 56,709 shares in the company, valued at $0.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09, SVP, General Counsel O’Malley Brendan M. bought 5,869 shares of the business’s stock. A total of $18,370 was incurred on buying the stock at an average price of $3.13. This leaves the insider owning 93,830 shares of the company worth $0.31 million. Insiders disposed of 137,211 shares of company stock worth roughly $0.45 million over the past 1 year. A total of 3.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ABEO stock. A new stake in Abeona Therapeutics Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $3,763,000. ARMISTICE CAPITAL, LLC invested $3,617,000 in shares of ABEO during the first quarter. In the first quarter, ECOR1 CAPITAL, LLC acquired a new stake in Abeona Therapeutics Inc. valued at approximately $3,554,000. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) acquired a new stake in ABEO for approximately $2,843,000. NANTAHALA CAPITAL MANAGEMENT, LLC purchased a new stake in ABEO valued at around $892,000 in the second quarter. In total, there are 36 active investors with 7.10% ownership of the company’s stock.
Wednesday morning saw Abeona Therapeutics Inc. (NASDAQ: ABEO) opened at $2.8700. During the past 12 months, Abeona Therapeutics Inc. has had a low of $2.19 and a high of $9.35. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.00, and a quick ratio of 2.00. The fifty day moving average price for ABEO is $2.6166 and a two-hundred day moving average price translates $3.6721 for the stock.
The latest earnings results from Abeona Therapeutics Inc. (NASDAQ: ABEO) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$1.48, beating analysts’ expectations of -$1.75 by 0.27. This compares to -$1.80 EPS in the same period last year. For the current quarter, analysts expect ABEO to generate $1M in revenue.
Abeona Therapeutics Inc.(ABEO) Company Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
